Correction to: Journal of Investigative Dermatology (2007) 127, 2315–2322; doi:10.1038/sj.jid.5700875  by unknown
Unique and Recurrent Mutations in the Filaggrin Gene in Singaporean Chinese Patients with Ichthyosis Vulgaris
Journal of Investigative Dermatology (2008) 128, 2545; doi:10.1038/jid.2008.151
Correction to: Journal of Investigative Dermatology (2008) 128, 1669–1675; doi:10.1038/jid.2008.2
In the publication by Chen et al., the DNA fragment sizes described under Materials and Methods, under the section entitled
‘‘Mutation detection screening for R4307X,’’ are incorrect. The last sentence of this paragraph should read ‘‘The wild-type
allele resolved as 119, 140, 102, and 38-bp fragments, whereas the mutant allele gave fragments of 119, 140, 51, 51, and
38 bp.’’
The authors regret the error.
Cross-Cultural Inequivalence of Dermatology-Specific Health-Related Quality of Life Instruments in Psoriasis Patients
Journal of Investigative Dermatology (2008) 128, 2545; doi:10.1038/jid.2008.185
Correction to: Journal of Investigative Dermatology (2007) 127, 2315–2322; doi:10.1038/sj.jid.5700875
In the publication by Nijsten et al., the affiliations of Francesca Sampogna and Joel Gelfand were presented incorrectly.
Dr Sampogna’s affiliation is with Health Services Research Unit, Istituto Dermopatico dell’Immacolata IDI-IRCCS, Rome, Italy
(affiliation no. 4 in the published article), while Dr Gelfand’s affiliation is with Department of Dermatology and Center
for Clinical Epidemiology and Biostatistics, University of Pennsylvania, Philadelphia, Pennsylvania, USA (affiliation no. 5 in
the published article).
The authors regret the error.
Polymorphisms in Folate, Pyrimidine, and Purine Metabolism are Associated with Efficacy and Toxicity of Methotrexate in
Psoriasis
Journal of Investigative Dermatology (2008) 128, 2545–2546; doi:10.1038/jid.2008.200
Correction to: Journal of Investigative Dermatology (2007) 127, 1860–1867; doi:10.1038/sj.jid.5700808
In the publication by Campalani et al., the 5-aminoimidazole-4-carboxamide ribonucleotide transformylase (ATIC) 347 C4G
polymorphism was misnamed; the ATIC 347 C (wild-type) allele should have been called ‘‘ATIC 347 G (variant),’’ and vice
versa. When the data were originally presented, the authors reported the variant ATIC 347 G allele to be significantly more
frequent in psoriasis patients with abnormal serum procollagen III (P3P) values than in those with normal serum P3P values
(P¼0.043) following therapy with methotrexate, and in patients who discontinued methotrexate due to any adverse events
compared with patients who tolerated the drug (P¼ 0.038).
In view of the fact that the genotyping data are correct, the mis-naming of the ATIC alleles results in an opposite interpretation
of the results, as follows:
(1) The ATIC 347 G allele was significantly less frequent in patients who developed a raised P3P compared with those with a
normal P3P (P¼ 0.043). This was probably a dominant effect, as the variant homozygous and heterozygous genotypes
were also less frequent (P¼ 0.051, OR¼0.38 [0.14–1.02] 95% CI).
(2) The frequency of the ATIC 347 G allele was also significantly lower in patients who discontinued methotrexate due to any
adverse event than in patients who tolerated the drug (P¼0.038). ATIC 347 C4G variant homozygous genotypes were
also less frequent in this group of patients but not significantly so.
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